Finally, after conclusively demonstrating that JZL184 impairs VEGF synthesis in tumor cells and subsequently inhibits VEGFR2 activation of HUVECs, the aim was to investigate whether JZL184 also impairs the receptor-activating and proliferative effects of VEGF already present or just released. The gene discussed is KDR; the disease is neoplasm.